Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
NUVB Form 144 shows a planned insider sale of common stock. A holder has filed notice to sell 200,000 shares of Nuvation Bio common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,427,680.00. The shares are listed for sale on the NYSE with an approximate sale date of 11/19/2025. As of the filing, 342,833,433 shares of Nuvation Bio common stock were outstanding, which is a baseline figure for the company’s equity. The shares to be sold were acquired on 11/19/2025 by exercising stock options under a registered plan and paid for in cash.
Nuvation Bio Inc. released an updated corporate presentation and highlighted newly published positive Phase 2 data for its IDH1 inhibitor safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. In an open-label study of 27 patients, safusidenib achieved an objective response rate of 44.4%, and median duration of response was not yet estimable because no progression had occurred. As of the data cut-off on March 10, 2023, median progression-free survival had not been reached, with 87.9% of patients progression free at 24 months and median follow-up of 28 months, suggesting durable disease control.
Adverse events were mostly mild to moderate; grade 3 or higher treatment-related events occurred in 18.5% of patients, with no grade 5 events and 11.1% discontinuations. A Good Clinical Practice noncompliance issue in adverse event collection was addressed through re-investigation and re-collection of safety data. Nuvation Bio is advancing the G203 global randomized study of safusidenib as maintenance therapy in high-grade and high-risk grade 2 IDH1-mutant gliomas, with a protocol amendment to finalize it as a global Phase 3 trial. The primary endpoint is progression-free survival by blinded central review, which the U.S. Food and Drug Administration has agreed could support full approval.
NUVB filed a Form 144 notice for a proposed sale of its Class A common stock. The filing covers a planned sale of 15,000 Class A common shares on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $71,475. These 15,000 shares were acquired on 11/17/2025 by exercising stock options under a registered plan, paid for in cash on the same date. The filing notes that 342,833,433 shares of Class A common stock were outstanding, providing context for the size of the planned sale.
Nuvation Bio (NUVB) reported Q3 2025 results. Total revenue was $13.1 million versus $0.7 million a year ago, driven by the first commercial sales of IBTROZI in the U.S. Product revenue was $7.7 million, and collaboration and license revenue was $5.4 million. Cost of revenue was $3.3 million, yielding gross profit of $9.8 million.
Operating expenses were $66.2 million (R&D $28.8 million; SG&A $37.4 million). Loss from operations was $56.4 million and net loss was $55.8 million ($0.16 per share). Weighted average shares outstanding were 342.4 million.
Liquidity remained significant with $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025. During the nine months, the company received $150.0 million from a revenue interest financing agreement and $48.9 million in borrowings; operating cash outflow was $143.7 million. Total liabilities rose to $275.7 million, including $150.6 million related to the revenue interest financing and $47.1 million in long-term borrowings. IBTROZI began U.S. shipments in June 2025.
Nuvation Bio Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and, along with the related information, is furnished rather than filed under the Exchange Act and Securities Act, except as specifically incorporated by reference. The company’s Class A Common Stock (NUVB) and Redeemable Warrants (NUVB.WS) are listed on the NYSE.
Nuvation Bio (NUVB) insider transaction: The Chief Scientific Officer executed a stock option exercise for 100,000 Class A shares at $1.74 (code M) on 10/27/2025 and sold 100,000 shares at a weighted-average price of $5.0246 (code S) pursuant to a Rule 10b5-1 plan dated June 24, 2024.
Following the transactions, non-derivative holdings were 0 shares. Derivative holdings included 298,935 stock options. The option grant referenced vests 25% on July 1, 2020, with the remainder in equal monthly installments over three years.
NUVB filed a Form 144 notice indicating a planned sale of 100,000 common shares. The filing lists an aggregate market value of $485,000 and identifies Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) as the broker. The approximate date of sale is 10/27/2025, and the shares are listed on the NYSE.
The seller acquired the shares on 10/27/2025 through an exercise of stock options from the issuer, with cash as the form of payment. The filing also notes 342,272,722 shares outstanding.
Robert Mashal, a director of Nuvation Bio Inc. (NUVB), reported derivative security transactions dated 08/11/2025 involving stock options with a $1.55 exercise/conversion price. The filing lists two entries of 350,001 option instruments each, with an exercisable/expiration date shown as 01/07/2034.
The filing states the shares underlying the options are fully vested and explains the reported transaction involved transfer of an option to the reporting person’s irrevocable trust. Post-transaction beneficial ownership shown on the form is 391,178 derivative securities held directly and 350,001 held indirectly (by trust).
Nuvation Bio (NUVB) Q2 2025 10-Q snapshot
- Total revenue rose to $4.83 million (vs. $1.44 million Q2 2024) driven by the first U.S. sales of IBTROZI ($1.24 million) and higher collaboration income.
- Gross profit reached $2.26 million; operating loss narrowed to $63.6 million from $470.4 million (prior period included $425 million IPR&D charge).
- Net loss was $59.0 million, or $0.17 per share, versus $462.5 million, or $1.89, a year ago. Six-month loss totals $112.2 million.
- Liquidity remains strong: cash and cash equivalents $247.9 million, marketable securities $359.8 million—about $607.7 million available, which management believes funds operations for ≥12 months.
- Balance-sheet leverage increased: $150 million revenue-interest financing and $47 million term loan lifted total liabilities to $274.3 million (up from $76.8 million at 12/31/24).
- R&D expense $27.4 million; SG&A $38.5 million support commercialization and pipeline. Shares outstanding: 342.3 million (7/31/25).
While the launch of IBTROZI establishes an initial revenue base, sustained losses, higher debt and continued heavy R&D spend underscore the need for successful market penetration and additional approvals to reach profitability.